Adjuvant treatment for high-risk endometrial cancer based on tumor genetics
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding an immunotherapy drug called durvalumab to the usual treatment can improve outcomes for people with a specific genetic type of endometrial cancer that is at high risk of returning. It is designed for people who have already had surgery to remove the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of endometrial cancer that is high risk and has spread beyond the uterus or into the lymph nodes.
- Your tumor has a specific genetic marker called MMR deficient, which means it has trouble repairing its DNA.
- You have fully recovered from surgery with no visible cancer left behind.
- You are 18 or older and have a good performance status (able to do your daily activities).
- Your organs (kidneys, liver, blood) are working well enough to safely receive the study drug.
- You have not had radiation therapy to the pelvis before, and you haven't had previous immunotherapy with PD-1 or PD-L1 inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two ways to treat endometrial cancer after surgery: a new option of just radiotherapy plus a daily hormone tablet (progestin) versus the current standard of radiotherapy plus chemotherapy. It aims to see if the new option works just as well with fewer side effects.
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
This trial tests a new combination of drugs for endometrial cancer that has spread or come back. It aims to see if these drugs can shrink tumors and help people live longer. It is for tumors that have a certain protein (HER2) and are mismatch repair proficient (meaning they have a normal DNA repair system).
This study tests whether using genetic information (molecular classification) along with standard factors helps decide if you should have radiation after surgery for early-stage uterine cancer. It aims to improve treatment and reduce side effects.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This trial tests whether radiation therapy after surgery is safe and effective for early-stage endometrial cancer. It is designed for patients with certain molecular subtypes and who have not had chemotherapy.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.